Furthermore, the protein levels of multiple RTKs (both phosphorylated and nonphosphorylated) were examined in KRAS-mutant NSCLC cells following trametinib treatment for 10 days. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.